IGF-BP7 Antibody
| Code | Size | Price |
|---|
| PSI-38-155-0.05mg | 0.05mg | £524.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Storage:
IGF-BP7 antibody is stable for at least 2 years from date of receipt at -20˚C. The reconstituted antibody is stable for at least two weeks at 2-8˚C. Frozen aliquots are stable for at least 6 months when stored at -20˚C. Avoid repeated freez
Documents
Further Information
Additional Names:
AGM, PSF, TAF, FSTL2, IBP-7, MAC25, IGFBP-7, RAMSVPS, IGFBP-7v, IGFBPRP1, Insulin-like growth factor-binding protein 7, IGFBP-rP1
Application Note:
ELISA:
Sandwich:
To detect hIGF-BP7 by sandwich ELISA (using 100 μ/well antibody solution) a concentration of 0.25 - 1.0 μg/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with our polyclonal Anti-Human IGF-BP7 as a capture antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIGF-BP7.
Western Blot:
To detect hIGF-BP7 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μg/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIGF-BP7 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Sandwich:
To detect hIGF-BP7 by sandwich ELISA (using 100 μ/well antibody solution) a concentration of 0.25 - 1.0 μg/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with our polyclonal Anti-Human IGF-BP7 as a capture antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIGF-BP7.
Western Blot:
To detect hIGF-BP7 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μg/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIGF-BP7 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Background:
IGF-BPs form high affinity complexes with both IGF-I and IGF-II and act to control of the distribution, function and activity of IGFs in various cell tissues and body fluids. There are seven named IGF-BPs. IGF-BP7 plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. IGF-BP7 is expressed in a wide range of normal human tissues and it usually shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin.
Concentration:
batch dependent
Conjugate:
Biotin
Immunogen:
Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hIGF-BP7. Human IGF-BP7 specific antibody was purified by affinity chromatography and then biotinylated.
NCBI Gene ID #:
3490
NCBI Official Name:
insulin-like growth factor binding protein 7
NCBI Official Symbol:
IGFBP7
NCBI Organism:
Homo sapiens
Physical State:
Lyophilized
Protein Accession #:
Q16270
Protein GI Number:
23396609
Research Area:
Antibody Pairs
Swissprot #:
Q16270
User NOte:
Centrifuge vial prior to opening.